Shares of Aurobindo Pharma Ltd are trading flat on 31st July after touching a day’s high of Rs 1,172.70, following the announcement that its wholly owned subsidiary, Aurobindo Pharma USA Inc., has entered into a definitive agreement to acquire 100% membership interest in Lannett Company LLC from Lannett Seller Holdco, Inc.

The deal is valued at $250 million (Rs 21,850 crore) on a cash-free, debt-free basis, including normalised working capital.

Lannett, founded in 1942 and based in Trevose, Pennsylvania, is a US manufacturer of complex generic drugs, including DEA-controlled substances. It specialises in non-opioid controlled substances, particularly ADHD treatments, and has launched several generic liquid products. The company operates a 425,000 sq. ft. cGMP facility in Seymour, Indiana, with an annual capacity of 3.6 billion tablets and a strong compliance record.

This acquisition supports Aurobindo’s plan to grow its US manufacturing footprint and strengthen its domestic market presence. It adds a complementary product portfolio, a growing CDMO business, and significant excess capacity for future expansion.

Aurobindo, which currently has limited exposure to ADHD therapies, will also diversify into this high-value segment. The deal, funded through cash, is subject to regulatory approvals, including clearance from the US FTC, and is expected to close within 8–12 months.

At 12:53 PM, the shares of Aurobindo Pharma were trading 0.17% higher at Rs 1,160 on NSE.

Tired of missing hot stocks? Unicorn Signals provides powerful tools like stock scans and more help you make informed trading decisions. Download now and take control of your portfolio!